$9.03
0.88% yesterday
Nasdaq, Dec 24, 07:01 pm CET
ISIN
US3984384087
Symbol
GRFS

Grifols, S.A. Sponsored ADR Class B Stock price

$9.03
+0.67 8.01% 1M
+0.49 5.74% 6M
+1.59 21.37% YTD
+1.21 15.47% 1Y
+0.91 11.21% 3Y
-9.62 51.58% 5Y
-7.36 44.91% 10Y
+2.42 36.58% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
-0.08 0.88%
ISIN
US3984384087
Symbol
GRFS
Industry

Key metrics

Basic
Market capitalization
$7.9b
Enterprise Value
$18.3b
Net debt
$10.4b
Cash
$972.0m
Shares outstanding
679.7m
Valuation (TTM | estimate)
P/E
14.2 | 10.0
P/S
0.9 | 0.9
EV/Sales
2.1 | 2.0
EV/FCF
18.1
P/B
1.3
Dividends
DPS
$0.00
Yield 1Y | 5Y
0.0% | 1.1%
Growth 1Y | 5Y
- | -100.0%
Payout 1Y | 3Y
0.0% | 0.0%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$8.9b | $9.0b
EBITDA
$2.5b | $2.2b
EBIT
$1.6b | $1.6b
Net Income
$438.9m | $620.8m
Free Cash Flow
$1.0b
Growth (TTM | estimate)
Revenue
7.3% | 5.5%
EBITDA
1.1% | 40.1%
EBIT
35.9% | 19.3%
Net Income
158.9% | 235.4%
Free Cash Flow
509.4%
Margin (TTM | estimate)
Gross
39.1%
EBITDA
28.2% | 24.3%
EBIT
18.1%
Net
5.0% | 6.9%
Free Cash Flow
11.4%
Financial Health
Equity Ratio
27.5%
Return on Equity
2.7%
ROCE
7.7%
ROIC
-
Debt/Equity
1.9
More
EPS
$0.6
FCF per Share
$1.5
Short interest
0.4%
Employees
24k
Rev per Employee
$360.0k
Show more

Is Grifols, S.A. Sponsored ADR Class B a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Grifols, S.A. Sponsored ADR Class B Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Grifols, S.A. Sponsored ADR Class B forecast:

14x Buy
70%
4x Hold
20%
2x Sell
10%

Analyst Opinions

20 Analysts have issued a Grifols, S.A. Sponsored ADR Class B forecast:

Buy
70%
Hold
20%
Sell
10%

Financial data from Grifols, S.A. Sponsored ADR Class B

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
8,852 8,852
7% 7%
100%
- Direct Costs 5,392 5,392
7% 7%
61%
3,460 3,460
8% 8%
39%
- Selling and Administrative Expenses 1,324 1,324
12% 12%
15%
- Research and Development Expense 444 444
10% 10%
5%
2,493 2,493
1% 1%
28%
- Depreciation and Amortization 894 894
31% 31%
10%
EBIT (Operating Income) EBIT 1,599 1,599
36% 36%
18%
Net Profit 439 439
159% 159%
5%

In millions USD.

Don't miss a Thing! We will send you all news about Grifols, S.A. Sponsored ADR Class B directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Grifols, S.A. Sponsored ADR Class B Stock News

Positive
Seeking Alpha
16 days ago
Grifols, S.A. has executed a turnaround, with Q3 '25 results confirming improved fundamentals, reduced leverage, and restored dividend, supporting a renewed 'Buy' rating. GRFS now trades at a normalized P/E of 14-15x, but forward multiples drop below 9x, offering significant upside if growth forecasts materialize. Operational improvements include 7%+ revenue growth, double-digit EBITDA gains, p...
Neutral
Seeking Alpha
about 2 months ago
Grifols, S.A. (OTCPK:GIKLY) Q3 2025 Earnings Call November 4, 2025 12:30 PM EST Company Participants Daniel Segarra - Head of Investor Relations & Sustainability and Vice President Jose Ignacio Abia Buenache - CEO & Director Roland Wandeler - President of Biopharma Business Unit Rahul Srinivasan - Chief Financial Officer Conference Call Participants Charles Pitman - Barclays Bank PLC, Research ...
Positive
Seeking Alpha
about 2 months ago
Biotech stocks have rebounded after years of underperformance but remain well below their 2021 highs. Successful drug launches, strong trial results, and falling interest rates have boosted stock prices, while M&A activity pushes valuations higher. The biotech rally could be sustainable, analysts say, with biotech firms more disciplined and increasingly profitable, while startups avoid launchin...
More Grifols, S.A. Sponsored ADR Class B News

Company Profile

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Head office Spain
CEO Nacho Abia
Employees 23,833
Founded 1940
Website www.grifols.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today